Mental healthcare company developing and delivering psychedelic assisted therapies psychotherapy to transform the mental health landscape Numinus Wellness Inc. (CVE: NUMI) announced approval of its MAPS program by Health Canada.
Multidisciplinary Association for Psychedelics Studies (MAPS) is a sponsored single-arm open-label safety and feasibility study which is keen on evaluating the MDMA-assisted therapy for post-traumatic stress disorder (PTSD).
This project is being done in collaboration with MAPS Public Benefit Cooperation (MAPS PBC) which is a wholly owned subsidiary of MAPS. MAPS is a leading developer of MDMA-assisted therapy training programs, treatment protocols and research.
“We are thrilled that Health Canada has issued its No Objection Letter allowing this important study to proceed and, in doing so, potentially advance Canada toward a legal, regulated system for MDMA-assisted therapy. At Numinus, we are focused on expanding patient access to psychedelic-assisted therapies such as MDMA for PTSD, and we are gratified that our study will provide safety and outcome data to regulators to support integration of this treatment into mainstream mental health care,” said Numinus CEO, Payton Nyquvest.